images

The Evolving Landscape of FMT: Current Trends and Future Prospects

Fecal microbiota transplantation (FMT) has transformed from an obscure treatment to a growing medical research and clinical practice area. FMT involves transferring a sample of a donor’s healthy gut microbiome from their stool into the recipient’s gut, with the aim of restoring a healthy gut microbial community1–4.  Initially employed to treat recurrent Clostridioides difficile infection (rCDI), the promising outcomes have sparked an expansion of research evaluating the efficacy of FMT for a wide variety of both gastrointestinal (GI) and extra-intestinal conditions1,4–7. As the field progresses and the number of clinical trials grows, emerging trends and potential breakthroughs are paving the way for FMT's broader adoption and innovative applications3,5,8.

Current State of FMT Usage

FMT's adoption has accelerated significantly since its first documented use over 1,700 years ago in the 4th century in China and its re-emergence in the 1950s3,9. FMT is an approved and highly effective treatment for patients with recurrent Clostridium difficile infections (rCDI) who are non-responsive to antibiotic therapy5,10–14. FMT has demonstrated success in treating, decolonizing and preventing the recurrence of Clostridium difficile infections with high success rates and favourable safety profiles7,8,15–19. Actually, FMT has been reported to achieve over a 90% clinical resolution rate in rCDI patients, which far surpasses standard antibiotic therapies16,20.  

Beyond Clostridioides difficile: Where the Research is Headed

Over the last decade, scientific and clinical research utilizing FMT to modify gut microbiome to improve health and tackle areas of unmet medical need has grown, rooted in the successful outcomes and adoption of FMT for rCDI1,4–7. A growing body of clinical research indicates that FMT may be a useful treatment option for many GI conditions, including inflammatory bowel disease (IBD)21–23, irritable bowel syndrome (IBS)24–26, and other GI conditions such as cancer and constipation4–6. Additionally, the therapeutic use of FMT may not be confined to GI conditions, with a growing number of clinical and pre-clinical studies looking at the use of FMT in treating a wide range of extra-intestinal conditions, including metabolic disorders7,27–31, autism spectrum disorder32–34, Parkinson’s disease35–37, and multiple sclerosis38,39, among others such as cancer, arthritis, and autoimmune disorders4–6. While the research is promising, there is a lack of large randomized controlled clinical trials. However, the number of clinical trials is growing, with more than 500 publicly registered trials exploring FMT in May 2023, compared to less than 30 in 20133,5,8.

Emerging Trends in FMT

Standardization and Safety

As FMT gains greater interest, one of the current challenges is the need for standardization in donor screening and manufacturing requirements. Variability in donor screening, stool processing, and administration methods can affect the outcomes and safety of FMT products. While regulations around FMT are still developing worldwide, efforts are underway to create standardized and clearly documented FMT screening and manufacturing requirements to help mitigate risks and ensure high-quality, reliable products40–51.  In 2022, both the United States (FDA) and Australia (TGA) provided regulatory approvals for the use of FMT for recurrent cDiff; concurrently, regulators have begun to hold FMT manufacturers to similar standards of traditional pharmaceuticals, requiring Good Manufacturing Practices (GMP) and stricter regulatory oversite in the way of licences. In 2024, Novel Biome secured the first FMT Drug Establishment Licence from Health Canada, certifying that the products are GMP and can be exported to appropriate clinical targets worldwide.

Expansion of Product Types

The expansion of FMT product types to encompass more administration routes is revolutionizing treatment accessibility and effectiveness. Traditionally, FMT was administered via colonoscopy or enema, which, while effective, can be invasive and costly for patients52,53. The development of alternative delivery methods, such as oral capsules and oral powders (Novel Biome patent-pending product for patients who cannot swallow capsules), which are non-invasive and require fewer resources, has significantly broadened the accessibility of FMT and broadened the treatment possibilities52,54–57.

While colonoscopy is still considered the gold standard for FMT administration with a wealth of data and efficacy rates reported over 90%53,58–65, oral capsules have emerged as a game-changer. They are reported to be as effective as colonoscopy, are safe and non-invasive, and require fewer resources than colonoscopy11,19,52,54–57. Overall, the creation of new product types may allow for FMT to be more accessible and aesthetically pleasing for patients.

FMT Personalized Medicine: Donor and Recipient Matching

While we are still learning what best defines a “healthy” gut microbiome, there is a clear understanding that the composition and diversity of the gut microbiome play an important role.  A new area of research is looking into the possibility of matching an individual patient profile with a best-suited donor gut profile, which may enhance treatment efficacy and reduce adverse effects. While this concept is still in its infancy, it appears to hold significant promise as we know both a donor’s high diversity and composition of the gut microbiota and the recipient’s microbiome can impact the outcomes associated with FMT66–68. This concept of donor-recipient matching will require an enormous amount of data on the gut microbiome profiles and associated outcomes; this is an endeavour of great interest to Novel Biome, which is currently trying to understand how to embark on this task and hopefully improve FMT outcomes.

Conclusion

FMT is at a pivotal point in its development, with the possibility of expanding applications and innovative approaches on the horizon. As research continues to uncover the vast potential of the human microbiome, FMT is poised to play a critical role in the future of medicine, providing an option for areas of unmet medical need.

At Novel Biome, we're passionate about the importance of the gut microbiome and the transformative potential of Fecal Microbiota Transplantation (FMT) treatment to restore health. As an FMT contract manufacturer, we leverage our years of experience in FMT to manufacture high-quality FMT products utilizing our highly-screened donors and stringent manufacturing standards. If you are interested in learning more about our FMT products and manufacturing capabilities, please contact us HERE or to register as a clinical partner to order FMT products, click HERE.

References: 1. Choi, H. H. & Cho, Y.-S. 2016, 2. Gupta, S., Mullish, B. H. & Allegretti, J. R. 2021, 3. Ser, H.-L. et al. 2021, 4. Xu, M.-Q. 2015, 5. Allegretti, J. R. et al. 2019, 6. Brandt, L. J. & Aroniadis, O. C. 2013, 7. Rinott, E. et al. 2021, 8. Gerardin, Y. et al. 2021, 9. Borody, T. J., Brandt, L. J. & Paramsothy, S. 2014, 10. Cammarota, G. et al. 2015, 11. Kao, D. et al. 2017, 12. Lee, C. H. et al. 2016, 13. Lee, C. H. et al. 2019, 14. van Nood, E. et al. 2013, 15. Austin, M., Mellow, M. & Tierney, W. M. 2014, 16. Basson, A. R. et al. 2020, 17. Kelly, C. R. et al. 2016, 18. McCune, V. L., Struthers, J. K. & Hawkey, P. M. 2014, 19. Youngster, I. et al. 2014, 20. Quraishi, M. N. et al. 2017, 21. Aldars-García, L., Chaparro, M. & Gisbert, J. P. 2021, 22. Anderson, J. L., Edney, R. J. & Whelan, K. 2012, 23. Tan, P. et al. 2020, 24. Cruz-Aguliar, R. M. et al. 2019, 25. ElSalhy, M. et al. 2022, 26. Ianiro, G. et al. 2019, 27. Allegretti, J. R. et al. 2021, 28. Kootte, R. S. et al. 2017, 29. Proença, I. M. et al. 2020, 30. Rinott, E. et al. 2021, 31. Zhang et al. 2019, 32. Kang, D.-W. et al. 2017, 33. Kang, D.-W. et al. 2019, 34. Li, N. et al. 2021, 35. Huang, H. et al. 2019, 36. Segal, A. et al. 2021, 37. Sun, M.-F. et al. 2018, 38. Makkawi, S., Camara-Lemarroy, C. & Metz, L. 2018, 39. Engen, P. A. et al. 2020, 40. Jørgensen, S. M. D. et al. 2017, 41. Terveer, E. M. et al. 2017, 42. Cammarota, G. et al. 2017, 43. Cammarota, G. et al. 2019, 44. Sokol, H. et al. 2016, 45. Mullish, B. H. et al. 2018, 46. Kim, K. O. et al. 2019, 47. Carlson, P. E. 2020, 48. Bibbò, S. et al. 2020, 49. Edelstein, C., Daw, J. R. & Kassam, Z. 2016, 50. He, J. et al. 2021, 51. Hota, S. S. et al. 2019, 52. Ramai, D. et al. 2019, 53. Krajicek, E. et al. 2019, 54. Cold, F. et al. 2021, 55. Fadda, H. M. 2020, 56. Kassam, Z. et al. 2015, 57. Roggenbrod, S. et al. 2019, 58. Drekonja, D. et al. 2015, 59. Gough, E., Shaikh, H. & Manges, A. R. 2011, 60. Kassam, Z et al. 2013, 61. Persky, S. E. & Brandt, L. 2000, 62. Postigo, R. & Kim, J. H. 2012, 63. Rohlke, F. et al. 2010, 64. Smits, L. P. et al. 2013, 65. Yoon, S. S. & Brandt, L. J. 2010, 66. Kump, P. et al. 2018, 67. Wilson, B. C. et al. 2019, 68. Schmidt, T. S. B. et al. 2022.